1. 200PApalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study. (24th November 2019) Authors: Chung, B H; McQuarrie, K; Bjartell, A; Chowdhury, S; Pereira de Santana Gomes, A J; Özgüroğlu, M; Juárez Soto, Á; Merseburger, A S; Uemura, H; Ye, D; Given, R; Miladinovic, B; Li, N; Hudgens, S; Floden, L; Lopez-Gitlitz, A; Chi, K N; Agarwal, N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 851PDPatient-reported outcomes (PROs) from TITAN: A phase III, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC). (1st October 2019) Authors: Agarwal, N; McQuarrie, K; Bjartell, A; Chowdhury, S; Gomes, A J P D S; Chung, B H; Özgüroğlu, M; Soto, Á Juárez; Merseburger, A; Uemura, H; Ye, D; Given, R; Miladinovic, B; Dearden, L; Deprince, K; Naini, V; Lopez-Gitlitz, A; Chi, K N Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗